Related Experiment Video

Updated: Aug 15, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Transforming growth factor-beta1-induced Smad signaling, cell-cycle arrest and apoptosis in hepatoma cells

C L Buenemann1, C Willy, A Buchmann

  • 1Institute of Toxicology, University of Tübingen, Wilhelmstrabetae 56, D-72074 Tübingen, Germany.

Carcinogenesis
|March 10, 2001
PubMed

Insights

Transforming growth factor-beta1 (TGFbeta) signaling activates Smad proteins in hepatoma cells. While some cell lines resist TGFbeta

Area of Science:

  • Hepatoma cell biology
  • Molecular signaling pathways
  • Cancer research

Background:

  • Transforming growth factor-beta1 (TGFbeta) regulates liver cell proliferation and apoptosis.
  • Hepatoma cells escaping TGFbeta growth suppression may contribute to tumor development.
  • TGFbeta signaling involves receptor-mediated activation of Smad proteins.

Purpose of the Study:

  • Investigate TGFbeta-mediated primary signaling responses, cell cycle effects, and apoptosis in hepatoma cell lines.
  • Determine the functionality of the TGFbeta signaling pathway in different hepatoma models.
  • Identify potential mechanisms of resistance to TGFbeta-induced apoptosis.

Main Methods:

  • Utilized human (HepG2), rat (FTO-2B), and mouse (55.1c) hepatoma cell lines.
  • Assessed TGFbeta signaling via a Smad response-element-driven luciferase reporter assay.
  • Analyzed TGFbeta-inducible early gene activation using RT-PCR.
  • Evaluated TGFbeta effects on cell cycle arrest and apoptosis.

Main Results:

  • The primary TGFbeta signaling pathway, indicated by Smad reporter activity and early gene induction, was functional in all tested cell lines.
  • HepG2 cells were completely resistant to TGFbeta-induced growth arrest and apoptosis.
  • 55.1c cells showed slight susceptibility to TGFbeta-induced apoptosis, while FTO-2B cells exhibited partial G0/G1 arrest and strong apoptosis induction.
  • Dexamethasone, insulin, phenobarbital, and dieldrin inhibited TGFbeta-induced apoptosis in FTO-2B cells.
  • Only insulin significantly reduced TGFbeta-stimulated Smad reporter activity, suggesting other agents act downstream of Smad signaling.

Conclusions:

  • Hepatoma cell lines display differential responses to TGFbeta, particularly regarding apoptosis.
  • Resistance to TGFbeta-induced apoptosis may involve mechanisms downstream of primary Smad-mediated transcriptional responses.
  • Further investigation into these downstream pathways could reveal novel therapeutic targets for hepatoma treatment.

More Related Videos

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...